

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Cost Comparison

Darolutamide with androgen deprivation therapy for treating hormonesensitive metastatic prostate cancer ID6452

Provisional Stakeholder List

| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|---|--|
| Company Bayer (darolutamide) Patient/carer groups Black Health Agency for Equality Bob Champion Cancer Trust Cancer Black Care Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Orchid Pelican Cancer Foundation Prostate Cancer Research Prostate Cancer Support Organisation Prostate Cancer UK | General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government NHS Wales Joint Commissioning |
| Prostate Matters UK South Asian Health Foundation Specialised Healthcare Alliance Tackle Prostate Cancer Tenovus Cancer Care | Committee Possible comparator companies Accord (bicalutamide, docetaxel, relugolix) |
| Healthcare professional groups Association of Anaesthetists Association of Cancer Physicians Association of Surgeons of Great Britain and Ireland British Association of Urological Nurses British Geriatrics Society British Institute of Radiology British Oncology Pharmacy Association British Psychosocial Oncology Society | Amdipharm Mercury Company (flutamide) Astellas Pharma (enzalutamide) AstraZeneca (bicalutamide, goserelin) Bayer (cyproterone acetate) Ferring Pharmaceuticals (degarelix, triptorelin) Ipsen (triptorelin) Johnson and Johnson Innovative Medicine (apalutamide) Kent Pharma (cyproterone acetate) Mylan (flutamide) |

Provisional stakeholder list for the evaluation of darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452



| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|--|---|
| British Uro-Oncology Group Cancer Research UK Prostate Cancer Advisory group Royal College of Anaesthetists Royal College of General Practitioners | Neon Healthcare (buserelin) Sun Pharma (bicalutamide) Takeda (leuprorelin) Typharm (leuprorelin) |
| Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Urology Foundation | Relevant research groups Cochrane Urology Genomics England Institute of Cancer Research MRC Clinical Trials Unit Pro Cancer Research Fund Associated Public Health groups Public Health Wales UK Health Security Agency |
| Others Department of Health and Social Care Health Technology Wales NHS England | |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452





The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.